Skip to main content

Eterna Therapeutics Inc (ERNA) Stock

Eterna Therapeutics Inc Stock Details, Movements and Public Alerts

Stock Details

Eterna Therapeutics Inc (ERNA), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $0.32. Over the past 52 weeks, it has ranged between $0.27 and $4.50. This places the current price at 7.1% of its 52-week high and 18.5% above its 52-week low. Recent trading volume was recorded at 3,376,621. The 14-day Relative Strength Index (RSI) stands at 18.68, suggesting oversold conditions. The stock is currently trading below its 50-day moving average of $1.21 by 73.55%. Similarly, it is below its 200-day moving average of $1.77 by 81.92%. The MACD histogram is -0.08, indicating bearish momentum (MACD Line: -0.14, Signal Line: -0.07).

52-Week Range

$4.50 - $0.27

-92.89% from high · +18.52% from low

Avg Daily Volume

263,013

20-day average

100-day avg: 2,332,988

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

0.01

Below market average

Price to Book

2.16

EV/EBITDA

-0.29

EPS (TTM)

$56.32

Price to Sales

7721.97

Beta

6.74

More volatile than market

Q:How is ERNA valued relative to its earnings and growth?
Eterna Therapeutics Inc trades at a P/E ratio of 0.01, which is below the market average of approximately 20. This lower valuation could indicate the market has modest growth expectations, or it might represent an undervalued opportunity if the fundamentals are strong.
Q:What is ERNA's risk profile compared to the market?
With a beta of 6.74, Eterna Therapeutics Inc is significantly more volatile than the market. For every 10% market move, this stock tends to move 67% in the same direction. Higher beta stocks offer greater potential returns but with increased risk. The price-to-book ratio of 2.16 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

0.00%

Operating Margin

-992200.00%

EBITDA

$-9,851,000

Return on Equity

-2264.00%

Return on Assets

-89.30%

Revenue Growth (YoY)

-94.10%

Earnings Growth (YoY)

0.00%

Q:How profitable and efficient is ERNA's business model?
0 The operating margin of -992200.00% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -2264.00% and ROA at -89.30%, the company achieves moderate returns on invested capital.
Q:What are ERNA's recent growth trends?
Eterna Therapeutics Inc's revenue declined by 94.10% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions.0 These growth metrics should be evaluated against BIOTECHNOLOGY industry averages for proper context.

Company Size & Market

Market Cap

$7.7M

Revenue (TTM)

$1,000

Revenue/Share (TTM)

$0.00

Shares Outstanding

27.09M

Book Value/Share

$0.46

Asset Type

Common Stock

Q:What is ERNA's market capitalization and position?
Eterna Therapeutics Inc has a market capitalization of $7.7M, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 27.09M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.
Q:How does ERNA's price compare to its book value?
Eterna Therapeutics Inc's book value per share is $0.46, while the current stock price is $0.32, resulting in a price-to-book (P/B) ratio of 0.70. Trading below book value can indicate the market perceives challenges ahead, or it might represent a value opportunity if the assets are quality and earnings can recover. Value investors often screen for P/B ratios below 1.0. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$3.00

837.50% upside potential

Analyst Recommendations

No analyst ratings available

Q:How reliable are analyst predictions for ERNA?
0 analysts cover ERNA with 0% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The bearish sentiment could create opportunity if analysts are wrong. The consensus target of $3.00 implies 837.5% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on ERNA?
Current analyst recommendations:The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Mar 1, 2026, 02:43 AM

Technical Indicators

RSI (14-day)

18.68

Oversold

50-Day Moving Average

$1.21

-73.55% below MA-50

200-Day Moving Average

$1.77

-81.92% below MA-200

MACD Line

-0.14

MACD Signal

-0.07

MACD Histogram

-0.08

Bearish

Q:What does ERNA's RSI value tell investors?
The RSI (Relative Strength Index) for ERNA is currently 18.68, indicating the stock is in oversold territory (below 30). This indicates heavy selling pressure that may have pushed the price too low too fast. Oversold readings can present buying opportunities, but stocks can remain oversold in strong downtrends. Look for RSI to rise above 30 as a potential recovery signal. Combined with the price being below the 50-day moving average, this confirms bearish conditions.
Q:How should traders interpret ERNA's MACD and moving average crossovers?
MACD analysis shows the MACD line at -0.14 below the signal line at -0.07, with histogram at -0.08. This bearish crossover indicates downward pressure. The narrow histogram suggests a potential trend change ahead. The 50-day MA ($1.21) is below the 200-day MA ($1.77), forming a death cross pattern that often warns of extended weakness. Price is currently below both MAs, confirming weakness.

Indicators last updated: Feb 9, 2026, 12:32 AM

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for ERNA and get notified when the price changes.

Stay Ahead of the Market with Eterna Therapeutics Inc Alerts

Set up price alerts for Eterna Therapeutics Inc and get notified instantly when the price hits your target. Never miss an important price movement again.